Press coverage about Biostar Pharmaceuticals (NASDAQ:BSPM) has trended positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biostar Pharmaceuticals earned a news impact score of 0.47 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.2670637413866 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Biostar Pharmaceuticals (NASDAQ:BSPM) traded up 5.43% during trading on Monday, reaching $1.36. The company had a trading volume of 14,631 shares. The company’s market capitalization is $3.62 million. The firm has a 50-day moving average price of $1.36 and a 200-day moving average price of $1.67. Biostar Pharmaceuticals has a 52-week low of $1.18 and a 52-week high of $7.06.

Separately, ValuEngine cut Biostar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 9th.

COPYRIGHT VIOLATION WARNING: “Biostar Pharmaceuticals (BSPM) Getting Favorable News Coverage, Study Shows” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at

Biostar Pharmaceuticals Company Profile

Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).

Insider Buying and Selling by Quarter for Biostar Pharmaceuticals (NASDAQ:BSPM)

Receive News & Ratings for Biostar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.